Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19

Jena, Germany | 23 October 2019 | Carl Zeiss Meditec AG

As already announced on October 2, 2019, Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of EUR 1,459 million in fiscal year 2018/19 (past year: EUR 1,280.9 million) and has significantly expanded EBIT1 margin2, exceeding the initial forecast of 15.0% to 17.5%. Based on today’s new assessment, EBIT for fiscal year 2018/19 amounted to approx. EUR 264 million (past year: EUR 197.1 million), leading to an EBIT margin of 18.1%.

Upon publication of preliminary results on October 2, 2019, the company had anticipated a still higher EBIT margin for fiscal year 2018/19.

The shortfall was caused by higher operating expenses in the fourth quarter of fiscal year 2018/19, in part driven by the already announced higher investments in the fields of Surgical Ophthalmology and Digitalization.
Final results for fiscal year 2018/19 will be provided on December 6, 2019.

Press Contact

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,050 employees worldwide, the Group generated revenue of €1,280.9m in fiscal year 2017/18 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

More information about Carl Zeiss Meditec AG Less information about Carl Zeiss Meditec AG
Press Contact

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com

Share
Further Articles

Insider Information

Carl Zeiss Meditec AG achieves significant growth in revenue and profit in fiscal year 2018/19

2 Oct 2019

Information pursuant

Carl Zeiss Meditec is aiming for the upper end of its revenue forecast for the current year and expects strong earnings

Carl Zeiss Meditec (ISIN: DE0005313704) has achieved revenue of around EUR 1,028 million in the first nine months of ...

16 Jul 2019

insider information pursuant to Art. 17 MAR

Further Growth

Carl Zeiss Meditec AG reports further growth and defines expectations for fiscal year 2018/19

12 Apr 2019